# A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01584232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01584232](<https://clinicaltrials.gov/study/NCT01584232>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01584232

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.

## Technical summary

Registry record NCT01584232. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2014-10-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 361 participants (enrolled count; ClinicalTrials.gov record NCT01584232, source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01584232, source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01584232, source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)
- Completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01584232, source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)
- Results first posted: 2014-10-20 (ClinicalTrials.gov record NCT01584232, source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01584232, source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01584232-2014-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): LY2189265
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Sulfonylureas (SU)
- Intervention (Drug): Biguanide (BG)
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: bc07b0fcd2fcd771c6a0be92a33fd8681717eadf6afec4b9f8b3fe7a3d1f2f65
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
